A diverse array of successful, first-generation SARS-CoV-2 vaccines have played a huge
role in efforts to bring the COVID-19 pandemic under control, even though inequitable …

Accumulating evidence shows a progressive decline in the efficacy of coronavirus disease
2019 (COVID‐19)(severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]) …

Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since …

Background Vaccine effectiveness against COVID-19 beyond 6 months remains
incompletely understood. We aimed to investigate the effectiveness of COVID-19 …

Background COVID-19 vaccines show excellent efficacy in clinical trials and effectiveness in
real-world data, but some people still become infected with SARS-CoV-2 after vaccination …

Background Despite high vaccine coverage and effectiveness, the incidence of symptomatic
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …

The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA
BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was …

Population antibody surveillance helps track immune responses to COVID-19 vaccinations
at scale, and identify host factors that may affect antibody production. We analyse data from …

Background Reports suggest that COVID-19 vaccine effectiveness is decreasing, but
whether this reflects waning or new SARS-CoV-2 variants—especially delta (B. 1.617. 2)—is …

COVID-19 vaccinations are essential to mitigate the pandemic and prevent severe SARS-
CoV-2 infections. However, the serum antibody levels in vaccinated individuals gradually …